NeoStem, Inc. NBS and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), announced
today the execution of a Services Agreement with Sentien Biotechnologies, Inc.
("Sentien") under which PCT will provide services to support Sentien's
development of its cell therapy product, including technology transfer, staff
training, and manufacturing.
Sentien is developing an allogeneic cell therapy product consisting of bone
marrow derived mesenchymal stem cells seeded onto a medical device for
critical care indications. Sentien has engaged PCT for manufacture of the
final formulation of its cell therapy product and intends to transfer and
implement Sentien's master cell bank, product working cell bank and product
manufacturing processes to PCT. These cell banks will be prepared according to
Good Manufacturing Practices ("GMP") guidelines and implemented by PCT to
create a cell therapy product for Sentien's Investigational New Drug ("IND")
submission to the FDA. Upon obtaining an IND, Sentien intends to have PCT
manufacture GMP compliant grade materials to support Sentien's Phase I
clinical trial.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in